Download Unicorn Signals App

Powered By EquityPandit
Latest News

Glenmark Pharmaceuticals signs an agreement with Celon for generic Seretide Accuhaler

Glenmark Pharmaceutical has entered into an agreement with Celon Pharma, Poland based company for developing and marketing a generic version of GlaxoSmithKline’s Seretide Accuhaler in Europe, which is used for the treatment of lung diseases.

Glenmark said in a statement that Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development and licensing agreement with Celon Pharma SA to develop and market a generic version of GSK’s Seretide Accuhaler product – fluticasone and salmeterol dry powder inhaler in Europe upon commercialisation.

It further added that “As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania, among others.”

Read EquityPandit’s Technical Analysis On CNX Pharma

Get Daily Prediction & Stocks Tips On Your Mobile